Please assess the completion status of the following clinical trial:

Trial Title: Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:60 consecutive patients with cirrhosis and refractory or recurrent ascites with stable renal function ( creatinine level \<1.5mg/dl for at least 7 days ).~Exclusion Criteria:~* Presence of gastrointestinal bleeding, HRS, hepatic encephalopathy of grade 2 or higher or infection within 1 month preceding the study or during the study, presence of diabetes, intrinsic renal or cardiovascular disease or arterial hypertension on history and physical examination, abnormal urine analysis, chest radiograph or electrocardiogram, presence of hepatocellular carcinoma or portal vein thrombosis or treatment with drugs with known effects on systemic and renal hemodynamics within 7 days of inclusion .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard medical therapy (Type: ACTIVE_COMPARATOR): Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
- Midodrine group (Type: ACTIVE_COMPARATOR): Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
- Tolvaptan group (Type: ACTIVE_COMPARATOR): Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
- Tolvaptan plus midodrine arm (Type: EXPERIMENTAL): Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).